NASDAQ:SNY

Sanofi Stock Forecast, Price & News

$53.80
+0.02 (+0.04 %)
(As of 06/11/2021 12:00 AM ET)
Add
Compare
Today's Range
$53.51
$53.91
50-Day Range
$49.79
$54.04
52-Week Range
$44.76
$55.00
Volume872,656 shs
Average Volume2.03 million shs
Market Capitalization$135.47 billion
P/E Ratio18.75
Dividend Yield2.55%
Beta0.58
30 days | 90 days | 365 days | Advanced Chart
Receive SNY News and Ratings via Email

Sign-up to receive the latest news and ratings for Sanofi and its competitors with MarketBeat's FREE daily newsletter.


Sanofi logo

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. The company provides specialty care products, including human monoclonal antibodies; products for multiple sclerosis, neurology, other inflammatory diseases, immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes; and cardiovascular and established prescription products. It also supplies poliomyelitis, pertussis, and hib pediatric vaccines; and influenza, adult booster, meningitis, and travel and endemic vaccines. In addition, the company offers allergy, cough and cold, pain, digestive, and nutritional products; and other products, such as daily body lotions, anti-itch products, moisturizing and soothing lotions, and body and foot creams, as well as powders for eczema. It also has various pharmaceutical products and vaccines in development stage. Sanofi has collaboration agreement with GlaxoSmithKline to develop a recombinant Covid-19 vaccine; and a research collaboration with Stanford University School of Medicine to advance the understanding of immunology and inflammation through open scientific exchange. It also has a collaboration with TrialSpark Inc. to execute clinical research studies in the areas of chronic obstructive pulmonary disease. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous

Social Links


MarketRank

Overall MarketRank

1.40 out of 5 stars

Medical Sector

731st out of 2,096 stocks

Pharmaceutical Preparations Industry

360th out of 830 stocks

Analyst Opinion: 0.0Community Rank: 2.0Dividend Strength: 2.5Insider Behavior: 0.0Valuation: 2.5 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Sanofi (NASDAQ:SNY) Frequently Asked Questions

Is Sanofi a buy right now?

9 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Sanofi in the last year. There are currently 1 sell rating, 4 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" Sanofi stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in SNY, but not buy additional shares or sell existing shares.
View analyst ratings for Sanofi
or view top-rated stocks.

What stocks does MarketBeat like better than Sanofi?

Wall Street analysts have given Sanofi a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Sanofi wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Sanofi's next earnings date?

Sanofi is scheduled to release its next quarterly earnings announcement on Wednesday, August 4th 2021.
View our earnings forecast for Sanofi
.

How were Sanofi's earnings last quarter?

Sanofi (NASDAQ:SNY) released its quarterly earnings data on Wednesday, April, 28th. The company reported $0.97 earnings per share for the quarter, beating analysts' consensus estimates of $0.83 by $0.14. The business had revenue of $8.59 billion for the quarter, compared to analyst estimates of $8.48 billion. Sanofi had a trailing twelve-month return on equity of 24.12% and a net margin of 17.33%. The company's revenue for the quarter was down 4.3% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.63 earnings per share.
View Sanofi's earnings history
.

How has Sanofi's stock price been impacted by COVID-19 (Coronavirus)?

Sanofi's stock was trading at $44.79 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, SNY stock has increased by 20.1% and is now trading at $53.80.
View which stocks have been most impacted by COVID-19
.

How often does Sanofi pay dividends? What is the dividend yield for Sanofi?

Sanofi announced an annual dividend on Thursday, March 25th. Stockholders of record on Tuesday, May 4th will be given a dividend of $1.9061 per share on Wednesday, May 26th. This represents a yield of 3.2%. The ex-dividend date of this dividend is Monday, May 3rd. This is a positive change from Sanofi's previous annual dividend of $1.21.
View Sanofi's dividend history
.

Is Sanofi a good dividend stock?

Sanofi pays an annual dividend of $1.37 per share and currently has a dividend yield of 2.55%. Sanofi does not yet have a strong track record of dividend growth. The dividend payout ratio of Sanofi is 40.90%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, Sanofi will have a dividend payout ratio of 32.08% next year. This indicates that Sanofi will be able to sustain or increase its dividend.
View Sanofi's dividend history.

Who are Sanofi's key executives?

Sanofi's management team includes the following people:
  • Mr. Paul Hudson, CEO & Director (Age 54, Pay $6.86M) (LinkedIn Profile)
  • Mr. Jean-Baptiste Chasseloup de Chatillon, Exec. VP & CFO (Age 56) (LinkedIn Profile)
  • Mr. Laurent Gilhodes, Principal Accounting Officer and VP of Corp. Accounting
  • Mr. Bruno Ménard, Chief Information officer
  • Dr. Josephine Fubara, Chief Science Officer of Consumer Health Care
  • Mr. George Grofik C.F.A., CPA, CFA, Head of Investor Relations
  • Ms. Karen Linehan, Exec. VP of Legal Affairs & Gen. Counsel (Age 62) (LinkedIn Profile)
  • Mr. Dante Beccaria, Global Compliance Officer & VP
  • Mr. Josep Catlla, Head of Communications
  • Mr. Pierre Chancel, Sr. VP of Global Diabetes and Sr. VP of Global Marketing (Age 64)

What is Paul Hudson's approval rating as Sanofi's CEO?

277 employees have rated Sanofi CEO Paul Hudson on Glassdoor.com. Paul Hudson has an approval rating of 94% among Sanofi's employees. This puts Paul Hudson in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Sanofi's key competitors?

What other stocks do shareholders of Sanofi own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Sanofi investors own include AbbVie (ABBV), Abbott Laboratories (ABT), Adobe (ADBE), Amgen (AMGN), Broadcom (AVGO), (AZN), The Boeing (BA), Alibaba Group (BABA), Bank of America (BAC) and BP (BP).

What is Sanofi's stock symbol?

Sanofi trades on the NASDAQ under the ticker symbol "SNY."

Who are Sanofi's major shareholders?

Sanofi's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Fisher Asset Management LLC (0.72%), BlackRock Inc. (0.60%), Price T Rowe Associates Inc. MD (0.17%), Lazard Asset Management LLC (0.12%), Morgan Stanley (0.10%) and Northern Trust Corp (0.10%).
View institutional ownership trends for Sanofi
.

Which institutional investors are selling Sanofi stock?

SNY stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, Schafer Cullen Capital Management Inc, JPMorgan Chase & Co., The Manufacturers Life Insurance Company, LSV Asset Management, Primecap Management Co. CA, Kestra Advisory Services LLC, and Eaton Vance Management.
View insider buying and selling activity for Sanofi
or view top insider-selling stocks.

Which institutional investors are buying Sanofi stock?

SNY stock was purchased by a variety of institutional investors in the last quarter, including Price T Rowe Associates Inc. MD, BlackRock Inc., Sphera Funds Management LTD., Cullen Capital Management LLC, Arrowstreet Capital Limited Partnership, Endurant Capital Management LP, Mondrian Investment Partners LTD, and Hamlin Capital Management LLC.
View insider buying and selling activity for Sanofi
or or view top insider-buying stocks.

How do I buy shares of Sanofi?

Shares of SNY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Sanofi's stock price today?

One share of SNY stock can currently be purchased for approximately $53.80.

How much money does Sanofi make?

Sanofi has a market capitalization of $135.47 billion and generates $41.17 billion in revenue each year. The company earns $14.07 billion in net income (profit) each year or $3.35 on an earnings per share basis.

How many employees does Sanofi have?

Sanofi employs 99,412 workers across the globe.

Does Sanofi have any subsidiaries?

The following companies are subsidiares of Sanofi: A. Nattermann & Cie. GmbH, AO Sanofi Russia, Ablynx, Ablynx N.V., Allston Landing Limited Partnership, Aventis Inc., Aventis Pharma (Manufacturing) Pte. Ltd, Aventis Pharma Limited, Aventis Pharma S.A., Aventis S.A., Aventisub LLC, Bioverativ, Bioverativ Inc., Bioverativ Therapeutics Inc., Bioverativ U.S.LLC, Carraig Insurance DAC, Chattem Inc., Chinoin Private Co. Ltd, Francopia, Genfar S.A., Genzyme Corporation, Genzyme Europe B.V., Genzyme Flanders BVBA, Genzyme Global Sarl, Genzyme Ireland Limited, Genzyme Limited, Genzyme Polyclonals SAS, Genzyme Therapeutic Products Limited Partnership, Genzyme Therapeutics Limited, Genzyme de Argentina S.A., Hoechst GmbH, Kiadis Pharma, Limited Liability Company Sanofi-Aventis Ukraine, PT Aventis Pharma, Principia BioPharma, SSP Co. Ltd, Sanofi (Beijing) Pharmaceuticals Co.Ltd, Sanofi (China) Investment Co. Ltd, Sanofi (Hangzhou) Pharmaceuticals Co. Ltd, Sanofi A/S, Sanofi AB, Sanofi Arabia Trading Company Limited, Sanofi Aventis NA Holding Inc., Sanofi Belgium, Sanofi Biotechnology, Sanofi Chimie, Sanofi Egypt, Sanofi Finance Ireland limited, Sanofi Foreign Participations B.V., Sanofi Healthcare India Private Limited, Sanofi Ilac Sanayi ve Ticaret A.S., Sanofi India Limited, Sanofi K.K., Sanofi Mature IP, Sanofi Medley Farmaceutica Ltda, Sanofi Nichi-Iko K.K., Sanofi Oy, Sanofi Pasteur, Sanofi Pasteur Asi Ticaret A.S., Sanofi Pasteur Biologies Co. Ltd, Sanofi Pasteur Europe, Sanofi Pasteur Inc., Sanofi Pasteur India Private Ltd, Sanofi Pasteur Limited, Sanofi Pasteur Ltd, Sanofi Pasteur NVL, Sanofi Pasteur S.A. de C.V., Sanofi Produtos Farmaceuticos Lda, Sanofi Romania SRL, Sanofi S.p.A., Sanofi Saglik Urunleri Limited Sirketi, Sanofi Taiwan Co. Ltd, Sanofi US Corporation, Sanofi US Services Inc., Sanofi Vaccine Technologies, Sanofi Winthrop Industrie, Sanofi-Aventis (Malaysia) SDN. BHD., Sanofi-Aventis (Suisse) SA, Sanofi-Aventis (Thailand) Ltd, Sanofi-Aventis A.E.B.E., Sanofi-Aventis Algérie, Sanofi-Aventis Argentina S.A., Sanofi-Aventis Australia Pty Ltd, Sanofi-Aventis Canada Inc., Sanofi-Aventis Deutschland GmbH, Sanofi-Aventis France, Sanofi-Aventis GmbH, Sanofi-Aventis Groupe, Sanofi-Aventis Gulf FZE, Sanofi-Aventis Healthcare Pty Ltd, Sanofi-Aventis Hong-Kong Limited, Sanofi-Aventis Ireland Ltd, Sanofi-Aventis Israël Ltd, Sanofi-Aventis Korea Co. Ltd, Sanofi-Aventis Liban s.a.l., Sanofi-Aventis Maroc, Sanofi-Aventis Netherlands B.V., Sanofi-Aventis Norge AS, Sanofi-Aventis Pakistan Limited, Sanofi-Aventis Participations, Sanofi-Aventis Philippines Inc., Sanofi-Aventis Private Co Ltd, Sanofi-Aventis Recherche & Développement, Sanofi-Aventis S.A., Sanofi-Aventis Singapore Pte. Ltd, Sanofi-Aventis South Africa (Pty) Ltd, Sanofi-Aventis Sp. z.o.o., Sanofi-Aventis U.S. LLC, Sanofi-Aventis UK Holdings Limited, Sanofi-Aventis Winthrop S.A. de C.V., Sanofi-Aventis de Colombia S.A., Sanofi-Aventis de Mexico S.A. de C.V., Sanofi-Aventis de Panama S.A., Sanofi-Aventis de Venezuela S.A., Sanofi-Aventis del Ecuador S.A., Sanofi-Aventis del Peru S.A., Sanofi-Aventis s.r.o., Sanofi-Synthelabo (India) Private Ltd, Sanofi-aventis Vietnam Company Limited, Shenzhen Sanofi pasteur Biological Products Co Ltd, Synthorx, VaxServe Inc., sanofi-aventis Puerto Rico Inc, and sanofi-aventis Slovakia s.r.o..

When was Sanofi founded?

Sanofi was founded in 2004.

What is Sanofi's official website?

The official website for Sanofi is www.sanofi.com.

Where are Sanofi's headquarters?

Sanofi is headquartered at 54 RUE LA BOETIE, PARIS I0, 75008.

How can I contact Sanofi?

Sanofi's mailing address is 54 RUE LA BOETIE, PARIS I0, 75008. The company can be reached via phone at 33 1 53 77 40 00 or via email at [email protected]


This page was last updated on 6/12/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.